Effects of G-CSF
on cardiac remodeling and arterial hyperplasia in rats.
As part of its coverage, the report provides the following: Scientific Differences of Pharmaceuticals and Biopharmaceuticals Market Share of Biosimilar Sales in Comparison to Brand Sales Marketed Biologics with Expired Patents Marketed Biologics with Active Patents Cost Savings From Biosimilar Use World Biosimilar Market Potential by Region 2010-2017 World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF
, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Biosimilars Pipeline by Company and Product Type
Dr Andrew Cuthbertson, Director of R&D at CSL said, "The G-CSF
inflammatory disease project is an excellent example of the strength of Australian medical research.
, myocardial infarction, stem cells OZET
The competition is fierce in China with about 20 G-CSF
products already in the market.
With genotype 2 and genotype 3 patients, we would need to treat 13 with erythropoietin or 54 with G-CSF
to obtain 1 additional SVR, when compared with dosage reductions of ribavirin or pegylated interferon, respectively The estimated cost for each SVR is $125,000-$500,000.
levels were significantly higher 1236 hours before delivery among those with funisitis (116.
At the Sloan-Kettering Cancer Center in New York City, 18 patients with a cancer called transitional-cell carcinoma were given G-CSF
after a standard chemotherapy regimen that depletes cell numbers.
Balugrastim is a recombinant G-CSF
fused to human albumin.
To order this report: The World Market for Biosimlars (EPO, G-CSF
, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition utm_campaign=Biopharmaceutical
In two randomized trials - one in patients with NHL, the other in patients with MM - Mozobil combined with G-CSF
increased the number of stem cells available for collection and transplantation compared with G-CSF
Kwizda Pharma of Austria had been working with IBPL to develop G-CSF
for the European market for some time.
Kirin has strong presence in hematology field through its product pipeline including CliniMACS, Busulfex and second-generation of G-CSF
According to G-CSF
Biosimilars Market Forecast to 2015, the overall market is presently dominated by first-generation biosimilars, and it is likely that their second-generation will grow phenomenally in the future.
A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF
in Healthy Volunteers